Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lutetium-177 rhPSMA10.1 - Blue Earth Therapeutics

Next Previous
Drug Profile

Lutetium-177 rhPSMA10.1 - Blue Earth Therapeutics

Alternative Names: 177Lu-rhPSMA10.1 - Blue Earth Therapeutics

Latest Information Update: 31 Jul 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Blue Earth Therapeutics
  • Class Antineoplastics; Imaging agents; Radioisotopes; Radiopharmaceutical diagnostics; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Prostate cancer

Most Recent Events

  • 29 Mar 2024 Phase-I/II clinical trials in Prostate cancer (First-line therapy, Late-stage disease, Neoadjuvant therapy, Monotherapy) in USA (Parenteral) (NCT06066437)
  • 11 Oct 2023 Preclinical trials in Prostate cancer (Diagnosis) in USA (IV) (NCT06066437)
  • 11 Oct 2023 M.D. Anderson Cancer Center and AVEO Pharmaceuticals plans a phase I/II trial for Prostate Cancer (Diagnosis) in USA (IV), in March 2024 (NCT06066437)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top